• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

消化性溃疡治疗的病理生理及药理学基础。

The pathophysiological and pharmacological basis of peptic ulcer therapy.

作者信息

Freston J W

机构信息

University of Connecticut Health Center, Farmington 06032.

出版信息

Toxicol Pathol. 1988;16(2):260-6. doi: 10.1177/019262338801600219.

DOI:10.1177/019262338801600219
PMID:2903542
Abstract

Both genetic and nongenetic factors predispose to ulcer diathesis. At the mucosal level ulcers result from an imbalance between aggressive factors and mucosal defense. Ulcer therapy reduces aggressive forces, bolsters defense, or both. Gastric acid, the major aggressive factor, may have its secretion inhibited or it may be partially neutralized by antacids. H2 receptor antagonists competitively block histamine occupancy of H2 receptors on parietal cells, thereby preventing stimulation of adenylate cyclase, cAMP rises, and activation of protein kinase and H+/K+ATPase. Prostaglandins inhibit acid secretion largely by preventing histamine-induced cAMP rises. Proton pump inhibitors bind H+/K+ATPase. Antimuscarinics inhibit acetylcholine receptors on the parietal cell, thereby blocking Ca2+ entry and subsequent activation of protein kinase and the proton pump. Mucosal defense is enhanced by certain prostaglandins, colloidal bismuth subcitrate and sucralfate. Prostaglandins stimulate secretion of bicarbonate and mucus, among other effects. Colloidal bismuth and sucralfate bind to proteins in the ulcer base and stimulate bicarbonate and mucus secretion, partially, in the case of sucralfate, by increasing endogenous prostanoid synthesis. Sucralfate also binds pepsin and bile acids. Colloidal bismuth temporarily eradicates mucosal colonization by Campylobacter pylori, another putative agent in ulcer diathesis.

摘要

遗传因素和非遗传因素均易导致溃疡素质。在黏膜层面,溃疡是由攻击因素与黏膜防御之间的失衡所致。溃疡治疗可降低攻击力量、增强防御或二者兼顾。胃酸是主要的攻击因素,其分泌可被抑制,或可被抗酸剂部分中和。H2受体拮抗剂竞争性阻断组胺对壁细胞上H2受体的占据,从而防止腺苷酸环化酶的刺激、cAMP升高以及蛋白激酶和H⁺/K⁺ATP酶的激活。前列腺素主要通过防止组胺诱导的cAMP升高来抑制胃酸分泌。质子泵抑制剂与H⁺/K⁺ATP酶结合。抗胆碱能药物抑制壁细胞上的乙酰胆碱受体,从而阻断Ca²⁺进入以及随后蛋白激酶和质子泵的激活。某些前列腺素、枸橼酸铋钾和硫糖铝可增强黏膜防御。前列腺素除其他作用外,还刺激碳酸氢盐和黏液的分泌。胶体铋和硫糖铝与溃疡底部的蛋白质结合,并刺激碳酸氢盐和黏液分泌,就硫糖铝而言,部分是通过增加内源性前列腺素的合成来实现的。硫糖铝还结合胃蛋白酶和胆汁酸。胶体铋可暂时根除幽门螺杆菌在黏膜的定植,幽门螺杆菌是溃疡素质中的另一种假定致病因素。

相似文献

1
The pathophysiological and pharmacological basis of peptic ulcer therapy.消化性溃疡治疗的病理生理及药理学基础。
Toxicol Pathol. 1988;16(2):260-6. doi: 10.1177/019262338801600219.
2
Drugs for treatment of peptic ulcers.治疗消化性溃疡的药物。
J Assoc Acad Minor Phys. 1992;3(3):78-88.
3
Pathogenesis and therapy of peptic ulcer disease.消化性溃疡病的发病机制与治疗
J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. doi: 10.1097/00004836-199000000-00002.
4
Medical treatment of peptic ulcers.消化性溃疡的医学治疗。
Surg Annu. 1985;17:219-33.
5
Current concepts in clinical therapeutics: peptic ulcer disease.临床治疗学的当前概念:消化性溃疡病
Clin Pharm. 1986 Feb;5(2):128-42.
6
[Pharmacologic treatment of ulcers].[溃疡的药物治疗]
Rev Med Univ Navarra. 1984 Jun;28(2):53-8.
7
Overview of medical therapy of peptic ulcer disease.消化性溃疡疾病的药物治疗概述
Gastroenterol Clin North Am. 1990 Mar;19(1):121-40.
8
Advances in the treatment of peptic ulcer disease.
Compr Ther. 1987 Aug;13(8):13-6.
9
Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.胃酸分泌的控制。组胺H2受体拮抗剂和H⁺K⁺-ATP酶抑制剂。
Gastroenterol Clin North Am. 1992 Sep;21(3):527-50.
10
Pharmacology of the treatment of peptic ulcer disease.消化性溃疡疾病的治疗药理学
Dig Dis Sci. 1985 Nov;30(11 Suppl):43S-51S. doi: 10.1007/BF01309384.

引用本文的文献

1
Apigenin attenuates indomethacin-induced gastric ulcer in rats: emphasis on antioxidant, anti-inflammatory, anti-apoptotic, and TGF-β1 enhancing activities.芹菜素减轻大鼠吲哚美辛诱导的胃溃疡:强调抗氧化、抗炎、抗凋亡和 TGF-β1 增强活性。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8803-8814. doi: 10.1007/s00210-024-03200-w. Epub 2024 Jun 6.